FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 13, 2013

THE FEMALE HEALTH COMPANY
(Exact name of registrant as specified in its charter)

Wisconsin
(State or other jurisdiction of incorporation)

1-13602
(Commission File Number)

39-1144397
(I.R.S. Employer I.D. Number)

515 North State Street
Suite 2225
Chicago, Illinois
(Address of Principal Executive Offices)

60654
(Zip Code)

312-595-9123
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 5 – Corporate Governance and Management

Item 5.02           Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On May 13, 2013, the Board of Directors (the "Board") of The Female Health Company (the "Company") appointed Andrew S. Love as a director of the Company for a term ending at the 2014 annual meeting of the shareholders. Mr. Love has not been appointed to any committee of the Board at this time.

Mr. Love is Chairman and Co-Chief Executive Officer of Love Savings Holding Company, the holding company of Heartland Bank. Mr. Love brings more than 40 years of investment, banking and real estate experience to the Board. He will be subject to the Company's standard compensation arrangement for non-employee directors, which is disclosed in the Company's proxy statement.

The Company's Nominating and Corporate Governance Committee recommended that Mr. Love be appointed as a director and the Board has concluded that Mr. Love is an "independent director" under the rules of the NASDAQ Stock Market.

A copy of the press release announcing the appointment of Mr. Love is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 5.03           Amendments to Articles of Incorporation or By-Laws; Change in Fiscal Year

On May 13, 2013, the Board adopted an amendment to the Amended and Restated By-Laws of the Company to provide that the number of directors of the Company will range from five to ten, as may be designated by the Board. The full text of the amendment to the Company's Amended and Restated By-Laws is filed as Exhibit 3.1 to this report and is incorporated herein by reference.

Section 9 - Financial Statements and Exhibits

Item 9.01.         Financial Statements and Exhibits.

(d)           Exhibits

3.1 -- Amendment to Amended and Restated By-Laws of The Female Health Company.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE FEMALE HEALTH COMPANY

Date: May 14, 2013

BY /s/ Michele Greco

Michele Greco, Vice President
and Chief Financial Officer
SECTION 3.01. General Powers and Numbers. The business and affairs of the Corporation shall be managed by its Board of Directors. The number of directors which shall constitute the whole Board shall be not less than five nor more than ten, as may be designated from time to time by resolution of the Board of Directors.
Andrew Love Joins
The Female Health Company
Board of Directors

CHICAGO, May 14, 2013 - The Female Health Company (NASDAQ-CM: FHCO - News), which manufactures and markets the FC2 Female Condom, today announced that it has named Andrew S. Love to be a member of its Board of Directors.

Mr. Love is Chairman of Love Savings Holding Company, the holding company of Heartland Bank, headquartered in St. Louis. The Love Companies have been active in real estate, banking and finance since 1875. Mr. Love has more than 40 years of experience in the investment, banking and real estate communities. Previously, Mr. Love was a partner at the law firm Bryan Cave, LLP.

Mr. Love has been a long time investor in, and supporter of, The Female Health Company. Mr. Love was one of the original investors in the Phoenix Limited Partnership whose general partner identified the female condom as an investment opportunity, which ultimately resulted in the creation of The Female Health Company.

Mr. Love has been a long time investor in, and supporter of, The Female Health Company. Mr. Love was one of the original investors in the Phoenix Limited Partnership whose general partner identified the female condom as an investment opportunity, which ultimately resulted in the creation of The Female Health Company.

Mr. Love has been a long time investor in, and supporter of, The Female Health Company. Mr. Love was one of the original investors in the Phoenix Limited Partnership whose general partner identified the female condom as an investment opportunity, which ultimately resulted in the creation of The Female Health Company.

Mr. Love holds an AB degree from Harvard College and an LLB degree from the Harvard Law School. Mr. Love has served as a board member for many charitable organizations, including the St. Louis Symphony Society, St. Louis Country Day School, St. Louis Repertory Theatre, the Center for Plant Conservation, Webster University, and the Edward K. Love Conservation Foundation.

O.B. Parrish, Chairman and CEO of The Female Health Company said: “We are delighted to have Andy Love as a member on our Board.”

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and approximately 139 other countries globally. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover the key aspects of FC2, including its overall design and manufacturing process. The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical fact are “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward-looking statements are inherently subject to known and unknown risks and uncertainties. The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward-looking statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity, efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the fiscal year ended September 30, 2012. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com.